Red tape hurt vaccine sales says Serum as it readies new intranasal trivalent flu product
This article was originally published in Scrip
Executive Summary
Serum Institute of India, the world's largest producer of the measles and diphtheria-tetanus-pertussis group of vaccines, is developing an intranasal trivalent influenza vaccine, but claims that government red tape has hurt the prospects of its already launched cut-price, indigenously developed intranasal H1N1 flu vaccine, Nasovac.